- IP Due Diligence
- ITC Litigation
- Intellectual Property
- Trademark & Copyright Protection
- Patent & Trade Secret Litigation
- Patent Preparation & Prosecution
|University ||Rutgers University, Ernest Mario School of Pharmacy, B.S., with honors, 2000|
|Law School||Seton Hall University, School of Law, J.D., magna cum laude, 2003|
|Admitted||2003, New Jersey; 2004, New York; U.S. District Court, Eastern District of New York; U.S. District Court, Southern District of New York; U.S. Patent and Trademark Office|
Andrew Chien's practice is focused in the area of intellectual property law, including litigation in the pharmaceuticals and medical devices fields, as well as client counseling, legal opinions, patent prosecution and transactions.
Andrew has experience in all aspects of litigation, including motion practice, expert preparation and all aspects of discovery practice. He has litigated in U.S. Federal Courts and in international arbitrations conducted under the WIPO rules. In addition to litigation, Andrew has experience with intellectual property issues surrounding mergers, acquisitions, and other transactions. For example, he assisted Elan in selling its interest in TYSABRI to Biogen Idec; Pfizer in intellectual property matters related to its acquisition of Wyeth; and Angiodynamic’s acquisition of Navilyst Medical.
In addition, Andrew has experience preparing and analyzing freedom-to-operate, validity and non-infringement opinions, as well as counseling a variety of international clients regarding patent procurement strategy and portfolio management in order to optimize patent protection.
Andrew received his J.D., magna cum laude, from Seton Hall University School of Law, where he was an editor of the Seton Hall Law Review, and a B.S. in Pharmacy, with honors, from the Rutgers University College of Pharmacy. Prior to joining Cadwalader, Andrew was an associate at Morgan & Finnegan in New York and Landman Corsi Ballaine & Ford in Newark, N.J.
He is admitted to practice in the States and Federal Courts of New York and New Jersey, as well as in the U.S. Patent and Trademark Office.
News & Resources
• Cadwalader Advises Acorda Therapeutics on Merger Agreement to Acquire Civitas Therapeutics
Sep 24, 2014
• Cadwalader Attorneys Honored with Burton Award for Excellence in Legal Writing for Sixth Time
Jun 02, 2009
Clients & Friends Memos
• New Decision Increases Calculation of Patent Term
Jan 16, 2014
• Congressional Breakthrough On Patent Reform Likely This Fall
Sep 14, 2011
• Global Patent Strategy
Oct 26, 2009
Representative intellectual property procurements and transactions:
•Acorda Therapeutics, Inc. in its pending acquisition of Civitas Therapeutics, Inc.
•Medinol Ltd., BIOrest Ltd. and Oscillon Ltd. in patent procurement and patent challenges.
•Elan’s sale of its interest in TYSABRI, a treatment for multiple sclerosis, to Biogen Idec.
•AngioDynamics, Inc.'s acquisition of Navilyst Medical.
•Pfizer, Inc.’s acquisition of Wyeth.
•JP Morgan in the securitization of intellectual property of various pledgors.
Pro bono intellectual property matters:
•Doors Wide Open’s trademark related to information on handicap accessible places.
•The Real News Project’s trademarks related to disseminating news information.
Documents by this lawyer on Martindale.com
New Decision Increases Calculation of Patent Term
Dorothy R. Auth,Andrew C. Chien, January 22, 2014
Yesterday, in Novartis AG v. Lee, 2013-1160 (Fed. Cir., Jan. 15, 2014), the Federal Circuit determined that the USPTO has been incorrectly calculating patent term adjustments, potentially shortening the terms of thousands of U.S. patents. Recently issued U.S. patents should be reviewed as soon as...
|Profile Visibility |
|#8,848 in weekly profile views out of 96,047 lawyers in New York, New York|
|#114,626 in weekly profile views out of 1,606,920 total lawyers Overall|